Related Experiment Video
Updated: Aug 6, 2026
07:50
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
Published on: July 16, 2012
[Biological agents targeting on pro-inflammatory cytokines]
1Department of Rheumatology/Clinical Immunology, Saitama Medical Center.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 17, 2005
Summary
Biologics targeting tumor necrosis factor (TNF) significantly improve rheumatoid arthritis (RA) by reducing inflammation and joint damage. This review covers the characteristics, efficacy, and safety of key anti-TNF agents used in RA treatment.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Context:
- Rheumatoid arthritis (RA) is a chronic inflammatory disorder impacting joints.
- Pro-inflammatory cytokines, particularly TNF, play a key role in RA pathogenesis.
- Biological agents offer targeted therapeutic strategies for RA management.
Purpose:
- To review the characteristics of anti-TNF biologics used in RA.
- To summarize the efficacy and safety profiles of these agents.
- To provide an overview of current anti-TNF therapies for rheumatoid arthritis.
Summary:
- Anti-tumor necrosis factor (TNF) biologics, including infliximab, adalimumab, and etanercept, are effective in treating rheumatoid arthritis (RA).
- These agents target key inflammatory pathways, leading to clinical improvement and structural joint protection.
- The review details the properties, therapeutic benefits, and safety considerations of these widely used RA treatments.
Impact:
- Provides clinicians with a comprehensive overview of anti-TNF therapies for RA.
- Highlights the clinical benefits and safety of biologics in managing inflammatory joint disease.
- Contributes to informed treatment decisions for rheumatoid arthritis patients.
Related Concept Videos
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...